Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Chronic Viral Infections and Cancer: Openings for Vaccines and Cure
share announcement

Chronic Viral Infections and Cancer: Openings for Vaccines and Cure

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 January 2027 | Viewed by 5272

Special Issue Editors

Dr. Maria G. Isaguliants

E-Mail Website
Guest Editor
Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia
Interests: chronic viral infections and associated cancer; human immunodeficiency virus type 1; human hepatitis C virus; oxidative stress; T cell response; B cell response; DNA vaccines
Special Issues, Collections and Topics in MDPI journals
Dr. Karl Ljungberg

E-Mail
Guest Editor
International Vaccine Institute (IVI), Stockholm, Sweden
Interests: vaccines; virology; immunology; infectious diseases; viral vectors

Special Issue Information

Dear Colleagues,

Specific human virus infections are the primary cause of cancer. These viral infections are estimated to lead to about 10% of the global cancer burden. Key oncogenic viruses include Hepatitis B virus (HBV), Human papillomaviruses (HPV), Hepatitis C virus (HCV), Epstein–Barr virus (EBV), Human immunodeficiency virus type I (HIV-1), Human T-cell leukemia virus type 1 (HTLV-1), and Human herpes virus 8 (HHV-8). HPVs exist in hundreds of genotypes, of which at least 14 are of high oncogenic risk (HR) and cause cancer in men and women, including anal, cervical, penile, throat, vaginal, and vulvar cancer. HR HPV- and HBV-associated cancers are the only cancers which currently can be prevented by prophylactic vaccination. HCV is a significant cause of liver cancer, but lacks a vaccine, although it can be treated with antiviral drugs. EBV is linked to several lymphomas and stomach cancer, and there is currently no vaccine for it. HIV-1, while not a direct cause of cancer, weakens the immune system and facilitates the development of cancers, with no available vaccine.

Understanding these oncogenic viruses has paved the way for interventions such as vaccines, screening for persistent infections, and antiviral therapies. Identifying additional oncogenic viruses and uncovering their mechanisms will further enhance preventive and therapeutic strategies against viral infections and related cancers.

This Special Issue welcomes submissions of experimental papers, short communications, reviews, and activity reports focusing on the above issues. Cordial invitation to submit is addressed to the speakers of the international online conference “Chronic viral infections and cancer, openings for vaccines and cure” VIRCAN2024 held at Riga Stradins University, Riga, Latvia, November 21–22, 2024 (https://www.rsu.lv/en/vircan2024-conference) and VIRCAN2026 planned at Riga Stradins University, Riga, Latvia, in November 2026.

Dr. Maria G. Isaguliants
Dr. Karl Ljungberg
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic viral infection
  • oncogenic viruses
  • hepatitis B virus
  • high risk human papillomaviruses
  • hepatitis C virus
  • epstein–barr virus
  • human immunodeficiency virus type I
  • cancer associated with viral infection
  • immunotherapy
  • prophylactic viral vaccines
  • therapeutic viral vaccines

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

17 pages, 1038 KB  
Review
SARS-CoV-2 Infection and Vaccination, Immune Dysregulation, and Cancer
by Dace Pjanova and Aysha Rafeeque
Vaccines 2026, 14(3), 255; https://doi.org/10.3390/vaccines14030255 - 11 Mar 2026
Viewed by 1854
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection induces heterogeneous immune responses that influence both acute disease severity and long-term immune remodeling. A key question in the context of infection and vaccination is whether SARS-CoV-2 exerts direct oncogenic effects or instead acts as [...] Read more.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection induces heterogeneous immune responses that influence both acute disease severity and long-term immune remodeling. A key question in the context of infection and vaccination is whether SARS-CoV-2 exerts direct oncogenic effects or instead acts as a transient immunological stressor capable of reinforcing tumor-permissive pathways. Current evidence does not support classical viral oncogenesis. Rather, severe infection is characterized by early interferon (IFN) imbalance followed by NF-κB-dominant inflammatory amplification, promoting sustained IL-6/JAK–STAT3 and MAPK signaling, chronic cytokine production, metabolic reprogramming, and impaired antitumor immune surveillance. At the molecular level, viral structural proteins modulate host signaling networks. The spike (S1) protein engages TLR2/TLR4–MyD88 pathways, activating NF-κB and MAPK cascades, while the membrane (M) protein reinforces NF-κB–STAT3 circuits linked to epithelial–mesenchymal transition and inflammatory gene expression. These mechanisms intensify pre-existing oncogenic signaling without initiating malignant transformation. Tissue-specific responses are further shaped by IFN competence, renin–angiotensin system balance, and metabolic context. In parallel, immune evasion programs shared by chronic viral infection and cancer, including checkpoint upregulation, impaired antigen presentation, and suppressive myeloid expansion, may be transiently reinforced following severe infection. In contrast, SARS-CoV-2 vaccination induces spatially restricted, self-limited innate activation without sustained inflammatory signaling or persistent antigen exposure. By preventing severe disease and chronic immune dysregulation, vaccination interrupts pathways hypothesized to intersect with cancer biology, with no evidence of increased cancer incidence. Ongoing longitudinal studies are required to clarify the long-term oncologic implications of post-infectious immune remodeling. Full article
(This article belongs to the Special Issue Chronic Viral Infections and Cancer: Openings for Vaccines and Cure)
►▼ Show Figures

Figure 1

16 pages, 802 KB  
Review
Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps
by Enkhtuul Batbold, Naranjargal Dashdorj, Fabien Zoulim and Birke Bartosch
Vaccines 2026, 14(2), 179; https://doi.org/10.3390/vaccines14020179 - 14 Feb 2026
Viewed by 1056
Abstract
Persistent infection with hepatitis D virus (HDV), also known as hepatitis delta, is considered the most severe form of chronic viral hepatitis. HDV is a defective RNA virus that depends on hepatitis B virus (HBV) for propagation. Despite its global distribution, HDV stays [...] Read more.
Persistent infection with hepatitis D virus (HDV), also known as hepatitis delta, is considered the most severe form of chronic viral hepatitis. HDV is a defective RNA virus that depends on hepatitis B virus (HBV) for propagation. Despite its global distribution, HDV stays a neglected part of the viral hepatitis agenda, often overlooked in surveillance systems and public health policy. This oversight is particularly concerning given HDV’s aggressive clinical course, characterized by more rapid progression to cirrhosis, liver failure, and hepatocellular carcinoma (HCC) compared to HBV mono-infection. Mongolia has the highest incidence and mortality rates of HCC worldwide, with approximately 47% of cases estimated to be attributable to chronic HDV infection. Globally, an estimated 12–25 million people are co-infected with HBV and HDV, although the true prevalence is higher due to insufficient screening and incomplete data collection. Because HDV infection is entirely dependent on HBV, prevention of HBV infection through effective vaccination stands for an indirect yet highly effective strategy to curb HDV transmission. The World Health Organization (WHO), together with the global health community, has established ambitious targets to eliminate viral hepatitis as a public health threat by 2030. However, achieving HDV elimination remains particularly challenging due to limited diagnostic capacity, low awareness, and minimal inclusion of HDV in national hepatitis programs. This review explores the intersection of HDV and HBV, focusing on how expanded and optimized HBV vaccination coverage can serve as a cornerstone of global HDV prevention efforts. We examine epidemiological evidence, scientific rationale, policy developments, and key implementation challenges, with particular attention to high-burden settings such as Mongolia. Finally, we propose strategic recommendations to bridge policy and practice gaps in HDV elimination. Full article
(This article belongs to the Special Issue Chronic Viral Infections and Cancer: Openings for Vaccines and Cure)
►▼ Show Figures

Figure 1

Other

Jump to: Review

24 pages, 347 KB  
Conference Report
Online Conference “Chronic Viral Infections and Cancer, Openings for Vaccines and Cure” VIRCAN2024, Monitoring the Progress
by Liba Sokolovska, Juris Jansons, Franco M. Buonaguro and Maria Isaguliants
Vaccines 2025, 13(9), 940; https://doi.org/10.3390/vaccines13090940 - 2 Sep 2025
Viewed by 1273
Abstract
Chronic viral infections and virus-induced cancers have been actively studied for decades, with many significant advancements in basic science, disease cure, treatment, and prevention. Yet, today, these infections and pathologies remain major contributors to morbidity and mortality worldwide. The international online conference “VIRCAN2024: [...] Read more.
Chronic viral infections and virus-induced cancers have been actively studied for decades, with many significant advancements in basic science, disease cure, treatment, and prevention. Yet, today, these infections and pathologies remain major contributors to morbidity and mortality worldwide. The international online conference “VIRCAN2024: Chronic viral infections and cancer, openings for Vaccines and Cure” aimed to address the remaining issues, present the research carried out in this broad field, and prognose directions for its development. The conference covered oncogenicity mechanisms and new approaches in the development of treatments and vaccines. VIRCAN2024 was held on the platform of Riga Stradins University, Riga, Latvia. The conference was supported by the Latvian Science Council grant “Human papillomavirus genome associated correlates of disease progression and treatment response for cervical neoplasms and cancer”, and the scientific journal Vaccines (MDPI). This report summarizes the lectures and presentations given at the conference. Full article
(This article belongs to the Special Issue Chronic Viral Infections and Cancer: Openings for Vaccines and Cure)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop